Navigation Links
Skinvisible Offers 8 Hour Photostablity for Parsol 1789

UVA Sunscreen with Invisicare Available For International Licensing

LAS VEGAS, July 29 /PRNewswire-FirstCall/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI)(,, the developers of Invisicare, a patented polymer delivery system that enhances topical skincare products, announces the successful development of a new broad spectrum sunscreen combining the active ingredient avobenzone (Parsol(R) 1789) with Invisicare. Avobenzone is one of only two UVA (320-400 nm) sunscreens approved in the USA. It is on the FDA's Category I sunscreen list, as it offers broad-range UVA protection and helps protect the skin against the harmful effects of sun which can cause skin cancers and premature skin aging.



"The results of the studies for our SPF 30 and 50 sunscreens are very impressive," said James Roszell, PhD for Skinvisible Pharmaceuticals. "Avobenzone is notoriously unstable when exposed to light with most products only offering two to four hours of protection. Skinvisible's sunscreens with Invisicare achieved eight hours of photostability with minimal degradation. Additionally, Invisicare has the ability to hold ingredients like avobenzone on the skin for extended periods of time, while resisting wash-off and perspiration; rating our sunscreen formulas as "very water-resistant".

"The completions of our studies are timely as the FDA reviews new labeling standards," said Mr. Terry Howlett, President and CEO of Skinvisible. "The FDA proposed changes to sunscreen labeling so that consumers can easily identify which sunscreen products offer UVA and UVB protection and at what level. This four-star ranking of UVA protection levels ranges from "low," "medium," "high" to "highest". We foresee that Skinvisible's new broad spectrum sunscreen would achieve the "highest" rating."

In addition to sunscreens, Skinvisible has a portfolio of 25 topical dermatology products formulated with Invisicare available for world-wide licensing. In addition to developing proprietary products for clients, Skinvisible's formulations include prescription, over-the-counter and cosmetic products for the treatment of acne, atopic dermatitis, fungal infections, as well as anti-inflammatories, analgesics, hand sanitizers, anti-aging, and sunless tanning products.

Parsol(R) 1789 -- registered trademark of DSM Nutritional Products.

About Invisicare(R) -- Invisicare is Skinvisible's patented polymer delivery system that offers "life-cycle management" and unique enhancements for topically delivered products. It is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time resisting both wash-off and perspiration. Invisicare controls the release of actives, reducing irritation and eliminating some costly manufacturing processes. It is non-occlusive and allows for normal skin respiration while protecting against environmental irritants.

About Skinvisible Pharmaceuticals, Inc. -- Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare(R) to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development, license, and royalties fees for the life of the Invisicare patent.

Forward-Looking Statements

This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending March 30, 2008)

Corporate Contact:

Doreen McMorran, VP Business Development

Skinvisible Pharmaceuticals, Inc

Phone: 702-433-7154


SOURCE Skinvisible, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Skinvisible Appoints New Vice President of Business Development & Marketing
2. Skinvisible Signs Licensing Agreement for Two Acne Formulations
3. Skinvisible Appoints New Board Member
4. Skinvisible Announces Licensing Agreement for Adapalene
5. Skinvisible Signs Marketing Agreement for India
6. Skinvisible Appoints Dr. George Korkos to Its Advisory Board
7. Skinvisible to Present at Merriman Curhan Ford & Co.s Investor Summit 2007
8. Geneva Offers First Cardiovascular Technology Graduate Program in the Nation
9. Automated, Wearable Kidney Offers Continuous Dialysis
10. Fairhope Vintners Offers First Release of Classically Styled Napa Valley Cabernet Sauvignon Wines
11. Vinson Hall Retirement Community Offers Glimpse into the Future of Retirement with Unique Innovative Model of Living
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical ... U.S. and is the only hospital in the region providing what is known ... of transcatheter pacing patients were revealed recently at a medical conference and published ...
(Date:12/1/2015)... MA (PRWEB) , ... December 01, 2015 , ... Growth ... in part due to decreases in utilization of hospital and nonhospital care, according to ... CompScope™ Medical Benchmarks for Louisiana, 16th Edition , found medical payments per claim ...
(Date:12/1/2015)... ... ... It’s official: Tattoo taboo is a thing of the past. One in ... whopping one in three aged 18 to 25 is inked). As tattoos transition to ... In fact, RealSelf , the world’s largest community for learning and sharing information ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... radiographic technicians must mark the film for accurate interpretation by the radiologist. The ... Fortunately, an inventor from Sacramento, Calif., has found a way to alleviate this ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... has been selected as a finalist in this year’s Fierce Innovation Awards: Healthcare ... IT Healthcare was recognized as a finalist in the category of Digital Solutions ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... -- ) has announced ... Disposables Market by product, by Animal - Global ... --> ) has announced the ... Market by product, by Animal - Global Forecast ... --> Research and Markets ( ) ...
(Date:12/1/2015)... 2015   MabVax Therapeutics Holdings, Inc . (OTCQB: ... has filed an Investigational New Drug Application (IND) with ... Company,s lead fully human antibody product HuMab 5B1 as ... to initiate the Phase I clinical trial early in ... The planned Phase I trial will evaluate the ...
(Date:12/1/2015)...  The migration to value-based care will require ... that help patients stay healthy and reduce healthcare ... enabled, incorporate care guidelines and be reflective of ... also allow all stakeholders to collaborate across care ... That is the vision, however, research by Chilmark ...
Breaking Medicine Technology: